Anebulo Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well-tolerated, and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
Anebulo Pharmaceuticals has raised $9.4M across 3 funding rounds on record, the most recent an undisclosed round of $1.9M announced in Nov 2024.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Anebulo Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Anebulo Pharmaceuticals Funding Rounds
Anebulo Pharmaceuticals raised $6.6M in a Post-IPO Equity announced in Sep 2022.
1.8 years later, an undisclosed round of $900k was announced in Jul 2024.
4 months later, an undisclosed round of $1.9M was announced in Nov 2024.
Anebulo Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Anebulo Pharmaceuticals Funding Compared to Other Biotechnology Startups
Anebulo Pharmaceuticals' latest round of $1.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Anebulo Pharmaceuticals in Biotechnology and Austin
Companies Similar to Anebulo Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Anebulo Pharmaceuticals Funding FAQs
What does Anebulo Pharmaceuticals do?
Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well-tolerated, and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
How much funding has Anebulo Pharmaceuticals raised?
Anebulo Pharmaceuticals has raised $9.4M across 3 rounds on record. The most recent is an undisclosed round of $1.9M announced in Nov 2024.
When did Anebulo Pharmaceuticals last raise funding?
Anebulo Pharmaceuticals' most recent funding round on record is an undisclosed round of $1.9M, announced in Nov 2024.
Who founded Anebulo Pharmaceuticals?
FundedIQ lists Joseph F Lawler (Founder) at Anebulo Pharmaceuticals.
Where is Anebulo Pharmaceuticals headquartered?
Anebulo Pharmaceuticals is based in Austin, Texas, United States.
How many employees does Anebulo Pharmaceuticals have?
Anebulo Pharmaceuticals is in the 1-10 employee band.
How does Anebulo Pharmaceuticals' funding compare to other Biotechnology startups?
Anebulo Pharmaceuticals' latest round of $1.9M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Anebulo Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Anebulo Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.